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Key Points
Question
What is the role of adjuvant therapy after curative-intent resection of ampullary adenocarcinoma?
Findings
In this cohort study that assessed 357 operative resections, neither fluorouracil-based nor gemcitabine-
based regimens were associated with improved survival, even when assessed relative to intestinal or
pancreatobiliary histologic subtype.
Meaning
The use of adjuvant chemotherapy, with or without radiotherapy, is not associated with improved long-term
survival after curative-intent resection of ampullary adenocarcinoma.
Abstract
Importance
Ampullary adenocarcinoma is a rare malignant neoplasm that arises within the duodenal ampullary
complex. The role of adjuvant therapy (AT) in the treatment of ampullary adenocarcinoma has not been
clearly defined.
Objective
To determine if long-term survival after curative-intent resection of ampullary adenocarcinoma may be
improved by selection of patients for AT directed by histologic subtype.
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Design, Setting, and Participants
This multinational, retrospective cohort study was conducted at 12 institutions from April 1, 2000, to July
31, 2017, among 357 patients with resected, nonmetastatic ampullary adenocarcinoma receiving surgery
alone or AT. Cox proportional hazards regression was used to identify covariates associated with overall
survival. The surgery alone and AT cohorts were matched 1:1 by propensity scores based on the likelihood
of receiving AT or by survival hazard from Cox modeling. Overall survival was compared with Kaplan-
Meier estimates.
Exposures
Adjuvant chemotherapy (fluorouracil- or gemcitabine-based) with or without radiotherapy.
Main Outcomes and Measures
Overall survival.
Results
A total of 357 patients (156 women and 201 men; median age, 65.8 years [interquartile range, 58-74 years])
underwent curative-intent resection of ampullary adenocarcinoma. Patients with intestinal subtype had a
longer median overall survival compared with those with pancreatobiliary subtype (77 vs 54 months; P = 
.05). Histologic subtype was not associated with AT administration (intestinal, 52.9% [101 of 191]; and
pancreatobiliary, 59.5% [78 of 131]; P = .24). Patients with pancreatobiliary histologic subtype most
commonly received gemcitabine-based regimens (71.0% [22 of 31]) or combinations of gemcitabine and
fluorouracil (12.9% [4 of 31]), whereas treatment of those with intestinal histologic subtype was more
varied (fluorouracil, 50.0% [17 of 34]; gemcitabine, 44.1% [15 of 34]; P = .01). In the propensity score–
matched cohort, AT was not associated with a survival benefit for either histologic subtype (intestinal:
hazard ratio, 1.21; 95% CI, 0.67-2.16; P = .53; pancreatobiliary: hazard ratio, 1.35; 95% CI, 0.66-2.76; P = 
.41).
Conclusions and Relevance
Adjuvant therapy was more frequently used in patients with poor prognostic factors but was not associated
with demonstrable improvements in survival, regardless of tumor histologic subtype. The value of a
multimodality regimen remains poorly defined.
Introduction
Ampulla of Vater adenocarcinoma is a rare malignant neoplasm that arises within the duodenal ampullary
complex.  Although it is associated with a more favorable prognosis than adenocarcinomas of the
adjacent pancreatic duct, common bile duct, or duodenum,  poor rates of long-term cure with surgical
resection alone make a compelling argument for a multimodality strategy for this disease.
To date, at least 4 randomized clinical trials have assessed the use of adjuvant therapy (AT) in resected
periampullary carcinoma,  although rarity of the disease has prohibited prospective study of
ampullary adenocarcinoma distinct from adjacent periampullary malignant neoplasms. Only the Japanese
Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract randomized
clinical trial, in which no survival benefit was observed for adjuvant mitomycin C and fluorouracil relative
to surgery alone (SA), included a subset analysis of patients with ampullary adenocarcinoma.  These trials
aggregated several periampullary malignant neoplasms with plausibly heterogeneous biological responses
to therapy, providing few prospective data from which to base treatment recommendations specific to
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ampullary cancers. Moreover, the ampulla represents the junction of the biliary, pancreatic, and digestive
tracts; as such, 2 major histologic phenotypes of ampullary adenocarcinoma (intestinal and
pancreatobiliary) have been identified.  The interaction between histologic subtype and response to
therapy is an underexplored topic.
Drawing on the collective experience of 12 pancreatic surgical institutions from 3 countries, this study
sought to examine contemporary factors associated with receipt of AT, the association of AT with survival,
and stratification of any association based on the histologic phenotype of ampullary adenocarcinoma.
Methods
Data were accrued from April 1, 2000, to July 31, 2017, for patients who underwent surgical resection of
ampullary adenocarcinoma performed at 12 institutions comprising the Ampullary Carcinoma Study
Group. Prospectively maintained institutional databases were retrospectively supplemented to accrue a data
list of patient demographics, perioperative outcomes, long-term recurrence, and survival. Pathology reports
were rereviewed and carcinomas of the adjacent pancreas, bile duct, or duodenum were excluded. The
study was approved by the University of Pennsylvania Institutional Review Board, who waived patient
consent because only deidentified data were obtained.
The primary outcome, overall survival (OS), was defined as the interval between the date of surgery and
date of death or last contact. Recurrence-free survival was defined as the interval between date of surgery
and date of recurrence or last contact or death not secondary to recurrent malignant neoplasm.
Adjuvant chemotherapy (AC) was defined by receipt of either single-agent or multiagent chemotherapy
initiated without palliative intent. When combined with radiotherapy, the regimen was classified as either
adjuvant chemoradiotherapy (ACRT) when given concurrently or as AC+ACRT when a chemotherapeutic
regimen was given temporally distinct from radiotherapy with a sensitizing chemotherapy agent.
Radiotherapy alone was not used in this patient cohort. Tumor stage was evaluated by surgical pathologic
findings and defined by the 8th edition of the American Joint Committee on Cancer’s Cancer Staging
Manual.
Histologic subtype was determined by institutional review of pathologic findings and did not necessarily
include immunohistochemical staining characteristics (eg, CDX or MUC1) given the strong correlation
between cytokeratin-immunohistochemistry and histologic classification.  Given this study’s focus on the
interaction between histologic characteristics and response to chemotherapy, patients with an unknown
histologic subtype were excluded from analysis.
The Fistula Risk Score was calculated for each pancreatoduodenectomy (PD) based on the weighted
influence of the following 4 risk factors: (1) pancreatic parenchyma, (2) pathologic characteristics of the
disease, (3) duct size, and (4) intraoperative blood loss.  Nonampullary adenocarcinoma PDs from the
Pancreas Fistula Study Group were used for comparative study of fistula risk and occurrence.  Clinically
relevant postoperative pancreatic fistula (CR-POPF) was defined in accordance with updated 2016
International Study Group on Pancreatic Surgery consensus guidelines,  and its occurrence and severity
was evaluated through 90 days after the index operation. Complications were scored according to the
Modified Accordion Severity Grading System and quantified using previously validated severity utility
weights.  Fistula mitigation strategies were used at the discretion of the operating surgeon. Prophylactic
octreotide was defined by its use as a preventive strategy and was generally started at the time of operation,
although certain surgeon practices included administration prior to the operation.
Statistical Analysis
Descriptive statistics are presented as frequencies and percentages for categorical variables and as mean
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and SD or median and interquartile range (IQR) for continuous variables. The Pearson χ  test was used to
analyze categorical and the Wilcoxon rank sum test was used to analyze continuous variables. Fixed-effects
regression modeling with stepwise elimination (P ≤ .05 for entry and P > .10 for removal) was used to
identify variables independently associated with AT. The influence of AT on OS was analyzed using Cox
proportional hazards regression modeling with backward stepwise selection (P ≤ .05 for entry and P > .10
for removal).
Propensity score matching (PSM) is a method used to minimize treatment selection bias when estimating
causal treatment outcomes in nonrandomized studies.  The SA and AT sets were matched 1:1 according to
propensity scores accounting for all factors associated with the use of AT or survival hazard on Cox
modeling (ie, age, race/ethnicity, pT classification, nodal status, and perineural invasion) using the
“greedy” nearest neighbor matching algorithm without replacement, with a caliper size of 0.1 × log(SD of
the propensity score).  After PSM, OS between the SA and AT groups was examined by Kaplan-Meier
estimates.
Missing data were rare and were addressed by including a category titled “unknown” for nominal variables
with missing data. Analyses were performed with SPSS, version 24.0 (IBM Corp). All P values were from
2-sided tests, and results were deemed statistically significant at P ≤ .05.
Results
Patient Demographics and Tumor Characteristics
A total of 756 patients with ampullary adenocarcinoma underwent curative-intent resection during the
study period. Serial exclusion of patients with unknown histologic characteristics (n = 369), in situ disease
as determined by final pathologic examination (n = 10), and inadequate follow-up (<30 days) (n = 14), as
well as those who died within 90 days of surgery (n = 6), yielded a final study cohort of 357 patients.
Median patient age was 65.8 years (IQR, 58-74 years), 201 (56.3%) were men, 156 (43.7%) were women,
and 311 (87.1%) were white (Table 1). Presenting symptoms included biliary obstruction (ie, jaundice or
cholangitis; 249 [69.7%]), abdominal pain (64 [17.9%]), weight loss (48 [13.4%]), bleeding or anemia (14
[3.9%]), and pancreatitis (10 [2.8%]). A total of 28 patients (7.8%) reported no symptoms prior to
diagnosis.
Pancreatoduodenectomy (354 [99.2%]) was the predominant operation performed (Table 1). Most surgical
procedures (243 [68.1%]) were pylorus preserving, and most patients (338 [94.7%]) underwent
pancreaticojejunostomy reconstruction. Final pathologic examination revealed a mean (SD) tumor diameter
of 2.4 (1.5) cm. Most patients (234 [65.5%]) had stage III disease. Adverse prognostic features, such as
poor differentiation (99 [27.7%]), lymphovascular invasion (227 [63.6%]), and perineural invasion (173
[48.5%]), were frequently observed. The most common histologic subtype was intestinal ([196] 54.9%),
followed by pancreatobiliary (138 [38.7%]) and mixed intestinal and pancreatobiliary variants ([16] 4.5%).
Perioperative Outcomes
Of the patients with ampullary adenocarcinoma with a known Fistula Risk Score who underwent PD (310
[86.8%]), the mean (SD) Fistula Risk Score was 4.3 (1.9), and most fistulas (218 of 310 [70.3%]) were in
the moderate risk zone. In comparison, the mean (SD) Fistula Risk Score of 4722 PDs comprising the
patients with nonampullary adenocarcinoma from the Pancreas Fistula Data Set  was significantly lower
(3.6 [2.2]; P < .001), with fewer cases of soft pancreatic texture (2499 of 4722 [52.9%] vs 229 of 310
[73.9%]; P < .001) and fewer cases within the moderate to high risk zone (3164 of 4722 [67.0%] vs 259 of
310 [83.5%]; P < .001) (eTable 1 in the Supplement). Accordingly, patients with ampullary
adenocarcinoma were significantly more likely to experience a CR-POPF (83 of 310 [26.8%] vs 557 of
2
20
21
16
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547142/?report=printable
5 of 19 7/17/2020, 3:41 PM
4722 [11.8%]; P < .001; odds ratio [OR], 2.73; 95% CI, 2.09-3.57) and have a longer hospital length of stay
(9 days [IQR, 7-15 days] vs 8 days [IQR, 7-13 days]; P = .002). There was no difference in the mean (SD)
fistula-specific accordion severity grade between patients with ampullary adenocarcinoma and those with
nonampullary adenocarcinoma (2.6 [0.9] vs 2.8 [1.2]; P = .08), meaning that CR-POPFs were not more
severe when they occurred.
Regarding fistula mitigation strategies, octreotide prophylaxis, biological sealants, and drain omission were
more frequently used in the ampullary adenocarcinoma cohort. However, there was no association between
CR-POPF and drain omission, octreotide prophylaxis, or biological sealant use in this cohort.
Use of Multimodality Therapies
Adjuvant therapy was administered to 200 patients (56.0%). Most of these 200 patients received AC (148
[74.0%]), with ACRT (21 [10.5%]) and AC+ACRT (31 [15.5%]) used less frequently. Of the patients who
received AC, 112 of 199 (56.3%) received a single-agent regimen, 75 of 199 (37.7%) received a multiagent
regimen, and 12 of 199 (6.0%) received an unknown regimen.
Univariate analysis demonstrated significant differences in patient and tumor characteristics between the
SA and AT (AC, ACRT, or AC+ACRT) cohorts (ie, age, race/ethnicity, pT classification, nodal
involvement, histologic grade, lymphovascular invasion, and perineural invasion). Histologic subtype
(intestinal vs pancreatobiliary) was not associated with AT administration (101 of 191 [52.9%] vs 78 of 131
[59.5%]; P = .24).
Variables significantly associated with AT receipt on univariate analysis (P ≤ .05) were entered into a
multivariable model to identify factors independently associated with use of AT. Node positivity (OR, 5.17;
95% CI, 3.01-8.87) and perineural invasion (OR, 2.74; 95% CI, 1.59-4.70) were independently associated
with receipt of AT, whereas older age (age >75 years: OR, 0.27; 95% CI, 0.14-0.55 [reference: age, ≤65
years]) and black race (OR, 0.26; 95% CI, 0.09-0.76 [reference: white]) were associated with the omission
of AT.
Influence of Adjuvant Therapy on Survival in Unmatched Cohort
The association of AT with OS was examined using Cox proportional hazards regression modeling
incorporating variables significantly associated with OS by univariate analysis (ie, age, race/ethnicity, pT
classification, nodal involvement, grade, lymphovascular invasion, perineural invasion, margin status, and
the use of AC). Patients with intestinal subtype had an improved median OS compared with those with
pancreatobiliary subtype (77 vs 54 months; P = .05). After adjusting for potential confounders and treating
institution, the use of AT was not independently associated with risk of death (Table 2). Pathologic stage
was associated with both the use of AT (stage I, 16 of 92 [17.4%]; stage II, 16 of 25 [64.0%]; and stage III,
168 of 227 [74.0%]; P < .001) and median OS (stage I, 137 months; stage II, 57 months; and stage III, 45
months; log-rank P < .001); however, AT was not associated with improved survival for any stage of
disease (eFigure 1 in the Supplement). In the patients who received AT, the addition of radiotherapy was
not associated with improvement in OS (ACRT: hazard ratio, 1.41; 95% CI, 0.78-2.55; AC+ACRT: hazard
ratio, 1.20; 95% CI, 0.66-2.20).
Efficacy of AT in the PSM Cohort
The PSM cohort comprised 162 patients: 81 (50.0%) in the SA group and 81 (50.0%) in the AT group.
Previously observed differences between cohorts were successfully balanced after matching (eTable 2 in
the Supplement). Most patients in the AT group received AC (64 [79.0%]) compared with ACRT (8
[9.9%]) or AC+ACRT (9 [11.1%]).
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At a median follow-up of 34 (IQR, 22-53) months, median OS in the PSM cohort was 57 months (IQR,
28-138 months); the 1-year actuarial survival rate was 89.3%, and the 5-year actuarial survival rate was
45.9%. Overall survival was not significantly different for patients receiving AT relative to SA (hazard
ratio, 0.90; 95% CI, 0.51-1.56; Figure 1A), including when they were stratified by stage (Figure 1B-D).
Association of AT With OS Stratified by Tumor Histologic Subtype
There was no significant difference in median OS between the 2 major histologic variants (intestinal, 59
months vs pancreatobiliary, 51 months; log-rank P = .12). No survival benefit was associated with AT for
either histologic subtype (intestinal: hazard ratio, 1.21; 95% CI, 0.67-2.16; P = .53; pancreatobiliary: hazard
ratio, 1.35; 95% CI, 0.66-2.76; P = .41).
To explore the potential association between tumor histologic subtype and association with OS based on
AT regimen used, the administered chemotherapies were dichotomized between fluorouracil-based
regimens and gemcitabine-based regimens. Fluorouracil-based regimens included monotherapy (10 of 68
[14.7%]) and multiagent therapies when combined with oxaliplatin (eg, XELOX [capecitabine and
oxaliplatin] or FOLFOX [leucovorin, fluorouracil, and oxaliplatin], 6 of 68 [8.8%]) or irinotecan (FOLFIRI
[fluorouracil, leucovorin, and irinotecan], 7 of 68 [10.3%]). Gemcitabine-based regimens included
monotherapy (31 of 68 [45.6%]) or multiagent therapy when combined with oxaliplatin (3 of 68 [4.4%]) or
abraxane (3 of 68 [4.4%]). Several patients received both gemcitabine and fluorouracil (6 of 68 [8.8%]).
Patients with the pancreatobiliary histologic subtype most commonly received gemcitabine-based regimens
(22 of 31 [71.0%]) or combinations of gemcitabine and fluorouracil (4 of 31 [12.9%]), whereas treatment
of the intestinal histologic subtype was more varied (fluorouracil, 17 of 34 [50.0%]; gemcitabine, 15 of 34
[44.1%]) (P = .01).
When limiting analysis to patients who received fluorouracil-based regimens, there was no association
between the use of AT and OS (Figure 2A), including when patients were stratified by intestinal (Figure 2
B) and pancreatobiliary (Figure 2C) histologic subtypes. There was no survival benefit associated with AT
when limited to patients who received multiagent therapy.
Likewise, use of gemcitabine-based regimens relative to SA was not associated with improved OS (
Figure 3A), with no difference for the subsets of patients with intestinal (Figure 3B) or pancreatobiliary (
Figure 3C) histologic subtype. There was no survival benefit associated with AT when limited to patients
who received multiagent therapy.
Outcome of the Addition of Radiotherapy to AC Regimens
In the PSM cohort, 17 of 81 patients (21.0%) received radiotherapy as part of their AT regimen. Most
patients (10 of 13 [76.9%]) received 50.4 Gy, and the remaining patients (3 of 13 [23.1%]) received 45.0
Gy. Radiotherapy-including regimens were not associated with improved OS relative to SA (hazard ratio,
0.77; 95% CI, 0.41-1.44; P = .41) or improvements relative to AC (hazard ratio, 1.58; 95% CI, 0.69-2.60;
P = .28).
Data on recurrence were available for 144 of the 162 patients in the PSM cohort (88.9%). Of 58 patients
(40.3%) who experienced a recurrence, the predominant pattern was distant (38 [65.5%]) rather than
locoregional (11 [19.0%]) or both (5 [8.6%]). The addition of radiotherapy to chemotherapy regimens was
not associated with improved recurrence-free survival relative to SA or AC (eFigure 2 in the Supplement).
Discussion
Ampullary carcinoma is a rare malignant neoplasm without established protocols for optimal multimodality
management after curative-intent resection. Without published guidelines from the National
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Comprehensive Cancer Network or the European Society for Medical Oncology, practice patterns have
been extrapolated from consensus guidelines for nearby periampullary malignant neoplasms. However,
whether the histomolecular phenotype defines discrete prognostic groups or can be used to guide selection
of AT has rarely been explored. To our knowledge, this multi-institutional study represents one of the
largest reported series of surgically resected ampullary adenocarcinomas with complete histologic and AT
details and highlights several important features regarding the overall management of these patients. In this
study, AT was used equally for patients with intestinal and pancreatobiliary histologic subtypes. However,
when AT was used, it was not associated with improvements in OS regardless of chemotherapeutic regimen
or the addition of radiotherapy. Moreover, among patients receiving AT, there was no interaction between
histologic subtype and long-term survival.
In this study, there was no survival benefit of AT in the multivariable model, which was also confirmed in
the PSM cohort. These results are corroborated by a recent meta-analysis involving 14 studies and 1671
patients, in which no survival advantage was seen with the use of AC or chemoradiotherapy.  That meta-
analysis did not exclude periampullary malignant neoplasms (eg, distal bile duct or duodenum), and it did
not have 3 of the 4 randomized clinical trials on this topic.
The merits of additive radiotherapy were also explored in the PSM cohort, and no benefit was observed
relative to SA or AC alone. That distant recurrence represents the most common pattern of disease relapse
(>60%) may explain such findings. Published data on this topic are discordant. Two randomized clinical
trials,  including the European Organisation for Research and Treatment of Cancer Trial 40891 of
fluorouracil and radiotherapy, failed to show a benefit, as did a PSM analysis of the Surveillance,
Epidemiology, and End Results data set.  On the other hand, a meta-analysis of 10 retrospective studies
demonstrated a significant advantage with adjuvant chemoradiotherapy ; this meta-analysis included the
positive study from the Johns Hopkins Hospital–Mayo Clinic collaboration.  The Mayo Clinic recently
published a follow-up, single-institution retrospective study of chemotherapy and/or chemoradiotherapy,
which demonstrated an independent association between AT and improved long-term survival.
Histomolecular phenotype has been cited as a factor independently associated with survival in patients with
ampullary carcinoma. At least 2 studies  have found a significant association between the
pancreatobiliary histologic subtype and poorer long-term survival. In our unmatched cohort, there was also
poorer medial OS in the pancreatobiliary subset (54 vs 77 months; P = .05). Histologic subtype was not
included in the multivariable Cox proportional hazards regression because it failed to meet the predefined
statistical threshold. Nevertheless, this seemingly different survival pattern has been cited to suggest that
ampullary carcinoma represents more than 1 distinct disease, with potential implications for therapeutic
strategies. However, in this study, there was no benefit for either fluorouracil-based or gemcitabine-based
regimens and no observable interaction between chemotherapeutic agent and histologic subtype. In
agreement with the European Study Group for Pancreatic Cancer-3 trial, in which no survival benefit was
observed for either leucovorin-modulated fluorouracil or single-agent gemcitabine relative to SA,  there
was no benefit to either chemotherapy regimen in this study. Although histologic subtype was associated
with type of chemotherapy administered in this series, there was no evidence that matching
chemotherapeutic regimen to histologic subtype was deferentially associated with survival.
Substratification in this 2-by-2 matrix likely left these analyses underpowered, although there were no
trends for any such comparisons. A post hoc analysis of the European Study Group for Pancreatic Cancer-3
trial found no significant improvement in survival for either the intestinal or pancreatobiliary histologic
subtypes, although further stratification by chemotherapeutic agent was not performed.
Limitations
Several limitations warrant emphasis. Because of this study’s retrospective and nonrandomized design,
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demonstrated associations cannot be interpreted as causative. Regression modeling and PSM are statistical
methods that can adjust for unbalanced covariates between study groups, although both are limited by the
potential influence of unmeasured confounders. The exclusion of patients who died within 90 days of
surgical resection was 1 method used to minimize the risk of the immortal time bias, a bias of observational
cohort studies in which patients who die prior to initiation of therapy are categorized into the control group,
which may exaggerate the apparent benefits seen in the treatment group. Second, while accounting for
numerous granularities not otherwise available in cancer registries, such as specific chemotherapeutic
agents and recurrence-free survival, there remain certain data omissions, such as treatment completion and
related treatment toxic effects, which are an important consideration in the decision for the use and type of
AT. Third, disease rarity may have limited the statistical power of certain analyses; however, given the
relative scarcity of this pathologic subtype (13% of all PDs performed in the Pancreas Fistula Study
Group), rigorous testing of these hypotheses may remain elusive. In particular, the subgroup analyses of
multiagent chemotherapy may have been underpowered given that gemcitabine monotherapy was the most
frequently used regimen in this series. The infrequent use of multiagent chemotherapy in this series may
have limited the efficacy of this overall strategy. Fourth, these data may not apply to the use of systemic
therapy in the neoadjuvant setting, a strategy not used in this series. The rate of CR-POPF was greater than
2-fold that observed among patients with nonampullary adenocarcinoma, likely driven by the higher rate of
soft gland texture with this pathologic subtype, which may limit receipt of all requisite therapy for this
high-risk disease. At least 1 study from the MD Anderson Cancer Center has demonstrated that
neoadjuvant therapy can be safely used for ampullary adenocarcinoma with no association with
perioperative morbidity or CR-POPF rates.
Conclusions
By analysis of this multi-national series, the use of chemotherapy, with or without radiotherapy, after
curative-intent resection of ampullary adenocarcinoma is not associated with improved long-term survival.
Neither intestinal nor pancreatobiliary histologic subtypes treated with AT were associated with improved
survival regardless of the chemotherapeutic agent used. Improvements in the care of patients with
ampullary adenocarcinoma will require identification of novel therapeutics and/or sequencing strategies to
improve long-term survival compared with the current agents.
Notes
Supplement.
eTable 1. Univariate Analysis of Operative Characteristics and Postoperative Outcomes of
Pancreatoduodenectomy, Stratified by Disease Pathology (n = 5082)
eTable 2. Demographic and Clinicopathologic Variables of the Propensity Score-Matched Cohort,
and Univariate Comparison Between Patients Receiving Surgery Alone or Adjuvant Therapy (n = 
162)
eFigure 1. Association of Adjuvant therapy and Overall Survival in the Unmatched Cohort,
Stratified by Pathologic Stage (stage I: n = 86; stage II: n = 21; stage III: n = 211)
eFigure 2. Association of Adjuvant Chemoradiotherapy Relative to Surgery Alone (left; n = 79) or
Chemotherapy Alone (right; n = 75) on Recurrence-Free Survival in the Propensity Score-Matched
Cohort
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Table 1.
Demographic and Clinicopathologic Characteristics of Overall Cohort
Open in a separate window
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); PJ,
pancreaticojejunostomy.
Race/ethnicity data missing for 16 patients.a
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Age data missing for 13 patients.
BMI data missing for 9 patients.
T classification data missing for 1 patient.
N classification data missing for 1 patient.
Histologic grade data missing for 12 patients.
Lymphovascular invasion data missing for 4 patients.
Perineural invasion data missing for 5 patients.
b
c
d
e
f
g
h
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Table 2.
Multivariable Cox Proportional Hazards Regression Modeling for Overall Survival Among
357 Unmatched Patients
Characteristic Hazard Ratio (95% CI) P Value
Age, y
<65 1 [Reference] .004
65-75 1.41 (0.88-2.27) .15
>75 2.67 (1.58-4.51) <.001
Race/ethnicity
White 1 [Reference] <.001
Black 3.93 (1.95-7.93) <.001
Asian or other 0.30 (0.04-2.28) .25
T classification
T1-2 1 [Reference] NA
T3-4 2.48 (1.60-3.84) <.001
N classification
Node-negative 1 [Reference] NA
Node-positive 2.52 (1.54-4.14) <.001
Grade
Well differentiated 1 [Reference] .24
Moderately differentiated NA .60
Poorly differentiated or undifferentiated NA .10
Lymphovascular invasion
Absent 1 [Reference] NA
Present NA .53
Perineural invasion
Absent 1 [Reference] NA
Present NA .05
Resection margin
Margin negative (R0) 1 [Reference] NA
Margin positive (R1-R2) NA .06
Adjuvant therapy
No 1 [Reference] NA
Open in a separate window
Abbreviation: NA, not applicable.
Hazard ratios indicate relative hazard for death and were adjusted for all variables included.
a
a
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Figure 1.
Association of Adjuvant Therapy and Overall Survival in the Propensity Score–Matched Cohort
A, Overall cohort (n = 148). B, Stage I (n = 30). C, Stage II (n = 19). D, Stage III (n = 99).
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Figure 2.
Open in a separate window
Association of Fluorouracil-Based Chemotherapy and Overall Survival in the Propensity Score–Matched Cohort
A, Overall cohort (n = 100). B, Intestinal histologic subtype (n = 61). C, Pancreatobiliary histologic subtype (n = 36).
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Figure 3.
Open in a separate window
Association of Gemcitabine-Based Chemotherapy and Overall Survival in the Propensity Score–Matched Cohort
A, Overall cohort (n = 127). B, Intestinal histologic subtype (n = 59). C, Pancreatobiliary histologic subtype (n = 54).
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